Congenital Adrenal Hyperplasia
- Author: Thomas A Wilson, MD; Chief Editor: Stephen Kemp, MD, PhD more...
Background
The term congenital adrenal hyperplasia (CAH) encompasses a group of autosomal recessive disorders, each of which involves a deficiency of an enzyme involved in the synthesis of cortisol,[1] aldosterone, or both.
Pathophysiology
The clinical manifestations of each form of congenital adrenal hyperplasia are related to the degree of cortisol deficiency and/or the degree of aldosterone deficiency. In some cases, these manifestations reflect the accumulation of precursor adrenocortical hormones. When present in supraphysiologic concentrations, these precursors cause abnormalities such as virilization or hypertension.
The phenotype depends on the degree or type of gene deletion or mutation and the resultant deficiency of the steroidogenic enzyme. The enzymes and corresponding genes are displayed in the image below.
Enzymes and genes involved in adrenal steroidogenesis. Two copies of an abnormal gene are required for disease to occur, and not all mutations and partial deletions result in disease. The phenotype can vary from clinically inapparent disease (occult or cryptic adrenal hyperplasia) to a mild form of disease that is expressed in adolescence or adulthood (nonclassic adrenal hyperplasia) to severe disease that results in adrenal insufficiency in infancy with or without virilization and salt wasting (classic adrenal hyperplasia). The most common form of adrenal hyperplasia (due to a deficiency of 21-hydroxylase activity) is clinically divided into 3 phenotypes: salt wasting, simple virilizing, and nonclassic.
CYP21A is the gene that codes for 21-hydroxylase, CYP11B1 codes for 11-beta-hydroxylase, and CYP17 codes for 17-alpha-hydroxylase. Many of the enzymes involved in cortisol and aldosterone syntheses are cytochrome P450 (CYP) proteins.
Epidemiology
Frequency
United States
The most common form of congenital adrenal hyperplasia is due to mutations or deletions of CYP21A, resulting in 21-hydroxylase deficiency. This deficiency accounts for more than 90% of adrenal hyperplasia cases. Mutations or partial deletions that affect CYP21A are common, with estimated frequencies as high as 1 in 3 individuals in selected populations (eg, Ashkenazi Jews) to 1 in 7 individuals in New York City. The estimated prevalence is 1 case per 60 individuals in the general population.
Classic adrenal hyperplasia has an overall prevalence of 1 case per 16,000 population; however, in selected populations (eg, the Yupik of Alaska), the prevalence is as high as 1 case in 400 population. Congenital adrenal hyperplasia caused by 11-beta-hydroxylase deficiency accounts for 5-8% of all congenital adrenal hyperplasia cases.
International
Congenital adrenal hyperplasia caused by 21-hydroxylase deficiency is found in all populations. 11-beta-hydroxylase deficiency is more common in persons of Moroccan or Iranian-Jewish descent.
Mortality/Morbidity
The morbidity of the various forms of adrenal hyperplasia is best understood in the context of the steroidogenic pathway, shown below, used by the adrenal glands and gonads.
Steroidogenic pathway for cortisol, aldosterone, and sex steroid synthesis. A mutation or deletion of any of the genes that code for enzymes involved in cortisol or aldosterone synthesis results in congenital adrenal hyperplasia. The particular phenotype that results depends on the sex of the individual, the location of the block in synthesis, and the severity of the genetic deletion or mutation. The clinical phenotype can be understood by analyzing the location of the enzyme deficiency, the accumulation of precursor hormones, and the physiologic action of those hormones (see History).
Severe forms of congenital adrenal hyperplasia are potentially fatal if unrecognized and untreated because of the severe cortisol and aldosterone deficiencies that result in salt wasting, hyponatremia, hyperkalemia, dehydration, and hypotension.
Race
Congenital adrenal hyperplasia occurs among people of all races. Congenital adrenal hyperplasia secondary to CYP21A1 mutations and deletions is particularly common among the Yupik Eskimos.
Sex
Because all forms of congenital adrenal hyperplasia are autosomal recessive disorders, both sexes are affected with equal frequency. However, because accumulated precursor hormones or associated impaired testosterone synthesis impacts sexual differentiation, the phenotypic consequences of mutations or deletions of a particular gene differ between the sexes.
Age
Classic congenital adrenal hyperplasia is generally recognized at birth or in early childhood because of ambiguous genitalia, salt wasting, or early virilization. Nonclassic adrenal hyperplasia is generally recognized at or after puberty because of oligomenorrhea or virilizing signs in females.
Merke DP. Approach to the adult with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab. Mar 2008;93(3):653-60. [Medline].
[Guideline] Torre JJ, Bloomgarden ZT, Dickey RA, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of hypertension. Endocr Pract. Mar-Apr 2006;12(2):193-222. [Medline].
McKusick VA. Online Mendelian Inheritance in Man. National Center for Biotechnology Information. Available at http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim.
Fluck CE, Tajima T, Pandey AV, et al. Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat Genet. Mar 2004;36(3):228-30. [Medline].
New MI, Rapaport R. The adrenal cortex. In: Pediatric Endocrinology. Philadelphia, Pa:. WB Saunders;1996:287.
Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. Sep 2010;95(9):4133-60. [Medline].
Gunther DF, Bukowski TP, Ritzen EM, et al. Prophylactic adrenalectomy of a three-year-old girl with congenital adrenal hyperplasia: pre- and postoperative studies. J Clin Endocrinol Metab. Oct 1997;82(10):3324-7. [Medline].
Barone MA, ed. The Harriet Lane Handbook. St Louis, Mo: Mosby-Year Book; 1996:681.
Vos AA, Bruinse HW. Congenital adrenal hyperplasia: do the benefits of prenatal treatment defeat the risks?. Obstet Gynecol Surv. Mar 2010;65(3):196-205. [Medline].
Carlson AD, Obeid JS, Kanellopoulou N, et al. Congenital adrenal hyperplasia: update on prenatal diagnosis and treatment. J Steroid Biochem Mol Biol. Apr-Jun 1999;69(1-6):19-29. [Medline].
Joint LWPES/ESPE CAH Working Group. Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. J Clin Endocrinol Metab. Sep 2002;87(9):4048-53. [Medline].
White PC. Neonatal screening for congenital adrenal hyperplasia. Nat Rev Endocrinol. Sep 2009;5(9):490-8. [Medline].
Aycan Z, Akbuga S, Cetinkaya E, et al. Final height of patients with classical congenital adrenal hyperplasia. Turk J Pediatr. Nov-Dec 2009;51(6):539-44. [Medline].
Garner PR. Congenital adrenal hyperplasia in pregnancy. Semin Perinatol. Dec 1998;22(6):446-56. [Medline].
Green-Golan L, Yates C, Drinkard B, et al. Patients with classic congenital adrenal hyperplasia have decreased epinephrine reserve and defective glycemic control during prolonged moderate-intensity exercise. J Clin Endocrinol Metab. Aug 2007;92(8):3019-24. [Medline].
Merke DP, Cutler GB Jr. New approaches to the treatment of congenital adrenal hyperplasia [clinical conference]. JAMA. Apr 2 1997;277(13):1073-6. [Medline].
Miller WL. Congenital adrenal hyperplasia in the adult patient. Adv Intern Med. 1999;44:155-73. [Medline].
Miller WL, Huang N, Pandey AV, et al. P450 oxidoreductase deficiency: a new disorder of steroidogenesis. Ann N Y Acad Sci. Dec 2005;1061:100-8. [Medline].
Miller WL, Strauss JF 3rd. Molecular pathology and mechanism of action of the steroidogenic acute regulatory protein, StAR. J Steroid Biochem Mol Biol. Apr-Jun 1999;69(1-6):131-41. [Medline].
New MI, Newfield RS. Congenital adrenal hyperplasia. Curr Ther Endocrinol Metab. 1997;6:179-87. [Medline].
Newell-Price J, Whiteman M, Rostami-Hodjegan A, et al. Modified-release hydrocortisone for circadian therapy: a proof-of-principle study in dexamethasone-suppressed normal volunteers. Clin Endocrinol (Oxf). Jan 2008;68(1):130-5. [Medline].
Pang S. Congenital adrenal hyperplasia. Endocrinol Metab Clin North Am. Dec 1997;26(4):853-91. [Medline].
Pang S. The molecular and clinical spectrum of 3 beta hydroxysteroid dehydrogenase deficiency disorder. Trend in Endocrinology and Metabolism. 1998;9(2):82-86.
Perry R, Kecha O, Paquette J, et al. Primary adrenal insufficiency in children: twenty years experience at the Sainte-Justine Hospital, Montreal. J Clin Endocrinol Metab. Jun 2005;90(6):3243-50. [Medline].
Purandare A, Godil MA, Prakash D, et al. Spontaneous adrenal hemorrhage associated with transient antiphospholipid antibody in a child. Clin Pediatr (Phila). Jun 2001;40(6):347-50. [Medline].
Skinner CA, Rumsby G, Honour JW. Single strand conformation polymorphism (SSCP) analysis for the detection of mutations in the CYP11B1 gene. J Clin Endocrinol Metab. Jun 1996;81(6):2389-93. [Medline].
Speiser PW, White PC. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency. Clin Endocrinol (Oxf). Oct 1998;49(4):411-7. [Medline].
Stratakis CA, Rennert OM. Congenital adrenal hyperplasia: molecular genetics and alternative approaches to treatment. Crit Rev Clin Lab Sci. Aug 1999;36(4):329-63. [Medline].
Wedell A. Molecular approaches for the diagnosis of 21-hydroxylase deficiency and congenital adrenal hyperplasia. Clin Lab Med. Mar 1996;16(1):125-37. [Medline].
White PC. Abnormalities of aldosterone synthesis and action in children. Curr Opin Pediatr. Aug 1997;9(4):424-30. [Medline].

